The short version of GHRH receptor fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-07-28. Anything still debated is marked as such rather than presented as settled.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | G-protein-coupled receptor on pituitary somatotrophs |
| Half-life, long-acting form | Several days | Extended by covalent albumin binding |
| Half-life, short form | About 30 minutes | Cleared rapidly by peptidases and kidneys |
| Route in studies | Subcutaneous injection | Used in the published human trials |
| Main measured effect | Rise in GH and IGF-1 | Surrogate markers rather than clinical endpoints |
In physics and chemistry, binding energy is the smallest amount of energy required to remove a particle from a system of particles or to disassemble a system of particles into individual parts. In the former meaning the term is predominantly used in condensed matter physics, atomic physics, and chemistry, whereas in nuclear physics the term separation energy is used. A bound system is typically at a lower energy level than its unbound constituents. According to relativity theory, a ΔE decrease in the total energy of a system is accompanied by a decrease Δm in the total mass, where Δmc2 = ΔE. There are several types of binding energy, each operating over a different distance and energy scale. The smaller the size of a bound system, the higher its associated binding energy.
==== Production of "Instant" 99mTc ==== The feasibility of 99mTc production with the 22-MeV-proton bombardment of a 100Mo target in medical cyclotrons was demonstrated in 1971. The recent shortages of 99mTc reignited the interest in the production of "instant" 99mTc by proton bombardment of isotopically enriched 100Mo targets (>99.5%) following the reaction 100Mo(p,2n)99mTc. Canada is commissioning such cyclotrons, designed by Advanced Cyclotron Systems, for 99mTc production at the University of Alberta and the Université de Sherbrooke, and is planning others at the University of British Columbia, TRIUMF, University of Saskatchewan and Lakehead University. A particular drawback of cyclotron production via (p,2n) on 100Mo is the significant co-production of 99gTc. The preferential in-growth of this nuclide occurs due to the larger reaction cross-section pathway leading to the ground state, which is almost five times higher at the cross-section maximum in comparison with the metastable one at the same energy. Depending on the time required to process the target material and recovery of 99mTc, the amount of 99mTc relative to 99gTc will continue to decrease, in turn reducing the specific activity of 99mTc available. It has been reported that ingrowth of 99gTc as well as the presence of other Tc isotopes can negatively affect subsequent labelling and/or imaging; however, the use of high purity 100Mo targets, specified proton beam energies, and appropriate time of use have shown to be sufficient for yielding 99mTc from a cyclotron comparable to that from a commercial generator.
=== Mixing with other insulins === The American Diabetes Association said in 2003 that, unlike some other longer-acting insulins, glargine should not be diluted or mixed with other insulin or solution in the same syringe, due to the low pH of its diluent. However, a 2004 study found that mixing glargine with other insulins did not affect short-term glycemic profile.
=== South Ossetia === The Government of South Ossetia in Tskhinvali called for Russian help to prevent "genocide" when the Georgian bombardment began, saying that Tskhinvali was under "the most frightful fire".
Sources: en.wikipedia.org
The 1984 "We begin bombing in five minutes" incident is an example of Cold War dark humor. It was a personal microphone gaffe joke between Ronald Reagan, his White House staff and radio technicians that was accidentally leaked to the US populace. At the time, Reagan was well known before this incident for telling Soviet/Russian jokes in televised debates, many of which have now been uploaded to video hosting websites.
=== Food storage === Xerophiles are a concern to food storage industry due to their ability to bypass common food preservation methods. Many foods are preserved by creating high osmotic pressures that dry out and kill any microbes that attempt to culture in the food. Foods such as honey or jam have such high levels of sugar and low levels of water normal micro organisms can not grow on them. However, xerophilic organisms can grow in these mediums posing a threat to food safety. The common food preservation methods of reducing water activity (food drying) may not always be sufficient to prevent the growth of xerophilic organisms, often resulting in food spoilage. Some mold and yeast species are xerophilic. Mold growth on bread is an example of food spoilage by xerophilic organisms. Complete dehydration based on the freeze-drying technique with effective protection inside a tight packaging system, strictly impervious to water and atmospheric gases (O2 and CO2), may be required for long-term preservation of food and pharmacochemical substances (antibiotics, vaccines...). Freeze drying can limit the microbial activity on the long term, as long as the product remains perfectly dry in a hermetically sealed and intact package, but it is not a sterilisation technique per se, because after rehydration, even if many dehydrated cells suffer irreversible and lethal damages, some resistant spores and bacterial endospores can still be revived again, and multiplied, by means of microbiological cultures if the product was not initially sterilized by applying a proven technique.
== History == The concept that insulin resistance may be the underlying cause of diabetes mellitus type 2 was first advanced by Professor Wilhelm Falta and published in Vienna in 1931, and confirmed as contributory by Sir Harold Percival Himsworth of the University College Hospital Medical Centre in London in 1936; however, type 2 diabetes does not occur unless there is concurrent failure of compensatory insulin secretion.
=== Discovery === Melatonin's discovery is linked to the study of color changes in some amphibians and reptiles, a phenomenon initially observed through the administration of pineal gland extracts. In 1917, Carey Pratt McCord and Floyd P. Allen found that feeding extracts from the pineal glands of cows caused the skin of tadpoles to lighten by contracting the dark epidermal melanophores. The hormone melatonin was isolated in 1958 by Aaron B. Lerner, a dermatology professor, and his team at Yale University. Motivated by the possibility that a substance from the pineal gland could be beneficial in treating skin diseases, they extracted and identified melatonin from bovine pineal gland extracts. Subsequent research in the mid-1970s by Lynch and others demonstrated that melatonin production follows a circadian rhythm in human pineal glands. The first patent for the therapeutic use of melatonin as a low-dose sleep aid was awarded to Richard Wurtman at the Massachusetts Institute of Technology in 1995.
== Disadvantages == The pharmaceutical client using the services of a CDMO does not have direct control of the project in regard to scheduling, cost, quality, or accountability yet should be heavily invested to work closely with the CDMO partner to ensure success. Data security can be an issue when considering a CDMO, as intellectual property and other proprietary data are exchanged between client and service provider. One of the major risk remains in the lack of control over the CDMO's compliance for the client, for example when an FDA warning letter is issued, a resulting interruption of production may result in major delay or interruption of shipping thus it is critical to properly vet the selected CDMO. The rise of the CDMO industry led to an increase of inspectors from various divisions of the Food and Drug Administration (e.g.: Center for Biologics Evaluation and Research or Center for Drug Evaluation and Research).
Sources: en.wikipedia.org
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.
The drug affinity complex links the peptide to serum albumin through a covalent bond. The conjugate is too large to be filtered quickly by the kidneys and is shielded from enzymatic breakdown. This extends the apparent half-life from roughly minutes to several days.
Long-term safety and any clinical benefit are unestablished. Published human data cover small groups over limited periods and focus on hormone levels rather than health outcomes. Whether prolonged elevation of growth hormone and insulin-like growth factor 1 is beneficial or harmful is an open question.